Premium
Decursin Exerts Anti‐cancer Activity in MDA‐MB‐231 Breast Cancer Cells Via Inhibition of the Pin1 Activity and Enhancement of the Pin1/p53 Association
Author(s) -
Kim JiHyun,
Jung Ji Hoon,
Kim SungHoon,
Jeong SooJin
Publication year - 2014
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.4986
Subject(s) - pin1 , breast cancer , medicine , cancer , cancer research , oncology , biology , biochemistry , enzyme , isomerase
The peptidyl‐prolyl cis/trans isomerase Pin1 is overexpressed in a wide variety of cancer cells and thus considered as an important target molecule for cancer therapy. This study demonstrates that decursin, a bioactive compound from Angelica gigas , exert the anti‐cancer effect against breast cancer cells via regulation of Pin1 and its related signaling molecules. We observed that decursin induced G1 arrest with decrease in cyclin D1 level in Pin1‐expressing breast cancer cells MDA‐MB‐231, but not Pin1‐non‐expressing breast cancer cells MDA‐MB‐157. In addition, decursin significantly reduced protein expression and enzymatic activity of Pin1 in MDA‐MB‐231 cells. Further, we found that decursin treatment enhanced the p53 expression level and failed to down‐regulate Pin1 in the cells transfected with p53 siRNA, indicating the importance of p53 in the decursin‐mediated Pin1 inhibition in MDA‐MB‐231 cells. Decursin stimulated association between Pin1 to p53. Moreover, decursin facilitated p53 transcription in MDA‐MB‐231 cells. Overall, our current study suggests the potential of decursin as an attractive cancer therapeutic agent for breast cancer by targeting Pin1 protein. Copyright © 2013 John Wiley & Sons, Ltd.